Literature DB >> 15191910

Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.

Meerana Lim1, Karen McKenzie, Alexandra D Floyd, Edwin Kwon, Pamela L Zeitlin.   

Abstract

Over 70% of patients with cystic fibrosis have the DeltaF508 mutation. This protein is a partially functional chloride (Cl-) channel that is prematurely degraded in the endoplasmic reticulum. Specific members of the flavonoid class of compounds have been shown to increase Cl- conductance of wild-type and DeltaF508 cystic fibrosis transmembrane regulator (CFTR). Although flavonoid effects on CFTR processing are unknown, evidence of effects on heat shock proteins, specifically those that have been shown to interact with CFTR, led us to believe that there would be an effect on CFTR processing through modulation of CFTR-chaperone interactions. We sought to determine (i) the effect of apigenin, genistein, kaempferol, and quercetin on CFTR processing in IB3-1 cells (F508/W1282X) and (ii) whether sequential treatment with 4-phenylbutyrate (4-PBA) to increase CFTR processing and flavonoid to directly stimulate CFTR would increase Cl- conductance. Our results show no significant effect on CFTR processing as measured by immunoblotting with 1 microM or 5 microM of apigenin, genistein, kaempferol, or quercetin. However, despite no effect on CFTR processing as determined by immunoblot, immunofluorescence demonstrated a favorable change in the intracellular distribution of CFTR with 24 h treatments of apigenin, kaempferol, and genistein. Furthermore, we observed an increase in Cl- conductance as measured by Cl- efflux in cells that were treated for 24 h with 4-PBA and then assayed with forskolin and 1 microM or 5 microM genistein, and also with cells treated for 24 h with either 4-PBA, 5 microM apigenin, or 1 microM quercetin. Thus, a combination of chronic treatment with 4-PBA or select flavonoids, followed by acute flavonoid exposure, may be beneficial in cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191910     DOI: 10.1165/rcmb.2002-0086OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  22 in total

1.  No amelioration of uromodulin maturation and trafficking defect by sodium 4-phenylbutyrate in vivo: studies in mouse models of uromodulin-associated kidney disease.

Authors:  Elisabeth Kemter; Stefanie Sklenak; Birgit Rathkolb; Martin Hrabě de Angelis; Eckhard Wolf; Bernhard Aigner; Ruediger Wanke
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

Review 2.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

3.  New Horizons in Correction of Mutated ATP7B in Wilson Disease Using Pharmacological Agents: Precise Medicine.

Authors:  Rajendra Prasad
Journal:  Indian J Clin Biochem       Date:  2019-10-16

Review 4.  Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment.

Authors:  Samuel M Moskowitz; Ronald L Gibson; Eric L Effmann
Journal:  Pediatr Radiol       Date:  2005-05-03

Review 5.  Rescuing the BMPR2 signaling axis in pulmonary arterial hypertension.

Authors:  James West; Eric Austin; Joshua P Fessel; James Loyd; Rizwan Hamid
Journal:  Drug Discov Today       Date:  2014-05-02       Impact factor: 7.851

Review 6.  Targets for cystic fibrosis therapy: proteomic analysis and correction of mutant cystic fibrosis transmembrane conductance regulator.

Authors:  James F Collawn; Lianwu Fu; Zsuzsa Bebok
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

7.  Critical roles for the COOH terminus of the Cu-ATPase ATP7B in protein stability, trans-Golgi network retention, copper sensing, and retrograde trafficking.

Authors:  L Braiterman; L Nyasae; F Leves; A L Hubbard
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-31       Impact factor: 4.052

8.  CFTR Modulators for the Treatment of Cystic Fibrosis.

Authors:  Rebecca S Pettit; Chris Fellner
Journal:  P T       Date:  2014-07

9.  Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator.

Authors:  A Schmidt; L K Hughes; Z Cai; F Mendes; H Li; D N Sheppard; M D Amaral
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

10.  Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue.

Authors:  Louise C Pyle; Jennifer C Fulton; Peter A Sloane; Kyle Backer; Marina Mazur; Jeevan Prasain; Stephen Barnes; J P Clancy; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-30       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.